The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. […]

Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?-cell destruction in type 1 diabetes (T1D), none of their target […]

Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?- cell destruction in type 1 diabetes (T1D), none of their target […]

Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?- cell destruction in type 1 diabetes (T1D), none of their target […]

Despite reaching an epidemic status worldwide, metabolic disorders, notably diabetes, still miss efficient and specific therapeutic strategies because […]

The present invention relates to methods and pharmaceutical compositions for the treatment of chronic kidney disease. The inventors used the CMap […]

GABA is an inducer of ?-to-?-like cell conversion in vivo. This conversion induces ? cell replacement mechanisms through the mobilization of […]

The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal […]

Type 1 diabetes (TID) is an autoimmune disease that results from the selective destruction of insulin-producing ?-cells in pancreatic islets. The […]

Use of Apelin in humans has a positive effect on insulin sensitivity with a good tolerance and a good safety. Thus, a first object of the invention […]